Ildong Pharmaceutical Completes Phase 2/3 Clinical Trials for COVID-19 Candidate Drug
[Asia Economy Reporter Lee Seon-ae] Ildong Pharmaceutical announced on the 26th that the Phase 2/3 clinical trial of the oral COVID-19 treatment candidate 'S-217622' has been completed at the Ministry of Food and Drug Safety (MFDS) in Korea.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- One in 77 Koreans Exposed to Drugs... Enough Money for 6,600 Luxury Gangnam Apartments Circulates in Drug Market [ChwiYakGukga] ⑩
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
They stated that efficacy was verified in Phase 2b and Phase 3 clinical trials targeting patients with mild to moderate infections.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
